摘要
目的:探讨复方田七胃痛胶囊联合以奥美拉唑肠溶胶囊为基础的三联疗法治疗消化性溃疡的临床疗效。方法:选择2016年5月-2017年10月我院消化科门诊收治的消化性溃疡患者86例,随机分为对照组(46例)和治疗组(40例)。对照组口服阿莫西林胶囊0.5 g/次,3次/d;奥美拉唑肠溶胶囊20 mg/次,2次/d;胶体果胶铋胶囊3粒/次,4次/d。治疗组在对照组的基础上增加复方田七胃痛胶囊4粒/次,3次/d。1月后评价疗效。比较临床疗效、幽门螺旋杆菌的消除情况以及6-酮-前列腺素F1α(6-ketone-ProstaglandinF1α,6-keto-PGF1α)。观察两组患者证候积分与血清中炎性分子水平。结果:治疗组临床疗效的有效率为93.47%,对照组的有效率为82.50%,两组比较差异显著,具有统计学意义(P<0.05)。治疗组的幽门螺旋杆菌根除率(87.50%),高于对照组(78.26%),两组比较差异显著,具有统计学意义(P<0.05)。治疗后两组6-keto-PGF1α水平均升高,与治疗前比较差异显著,均具有统计学意义(P<0.01);治疗组6-keto-PGF1α水平上升较对照组显著,两组差异具有统计学意义(P<0.01)。观察组患者各项证候积分均显著低于对照组,且血清中炎性分子水平均显著由于对照组,两组差异具有统计学意义(P<0.05)。结论:复方田七胃痛胶囊联合以奥美拉唑肠溶胶囊为基础的三联疗法对消化性溃疡具有较好的临床疗效,能加快溃疡愈合,其机制可能与提高胃黏膜6-keto-PGF1α有关。还能有效降低各项证候积分改善患者血清中炎性分子水平,是安全有效的药物治疗方案。
Objective:To investigate the clinical efficacy of the Fufang Tianqi Weitong capsules(复方田七胃痛胶囊)with triple therapy based on Omeprazole enteric coated capsules on peptic ulcer.Methods:86 cases were randomly divided into the control group and treatment group,with 46 and 40 cases,respectively.The patients in the control group were given Amoxicillin capsules,Omeprazole enteric coated capsules,Colloidal Bismuth Pectin capsules.The treatment group were given the Fufang Tianqi Weitong capsules more.Results:The efficiency in the treatment group was 93.47%,and 82.50%in the control group(P<0.05).The eradication rate in the treatment group(87.50%)was better than 78.26%in the control group(P<0.05).After treatment,levels of 6-keto-PGF1αin two groups were significantly increased(P<0.01),and that in the treatment group was better than the control group.The scores of symptoms in the observation group were significantly lower than those in the control group,and the levels of inflammatory molecules in serum were significantly lower than those in the control group(P<0.05).Conclusion:The Fufang Tianqi Weitong capsules with triple therapy was effective on peptic ulcer,can accelerate ulcer healing,and its mechanism may related to improvement of 6-keto-PGF1αlevels.It can also effectively reduce the scores of various symptoms and improve the level of inflammatory molecules in patients’serum.
出处
《中医临床研究》
2019年第20期40-42,共3页
Clinical Journal Of Chinese Medicine
